"Ośrodek Onkologiczny "Kopernik" sp. z o.o. prowadzi kompleksową diagnostykę i leczenie chorób onkologicznych, chorób piersi, zmian skórnych. W ramach Ośrodka działają poradnie onkologiczne, poradnie chirurgii onkologicznej, oddział chirurgii jednego dnia oraz oddział chemioterapii jednego dnia. Świadczymy usługi w oparciu o kontrakt z NFZ oraz prywatnie."

During the past decade, Olsztyński Ośrodek Onkologiczny Kopernik sp. z o.o. conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 6 clinical trials were completed, i.e. on average, 200% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 2 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Olsztyński Ośrodek Onkologiczny Kopernik sp. z o.o." #1 sponsor was "Hoffmann-La Roche" with 2 trials, followed by "Agennix" with 1 trials sponsored, "Celgene" with 1 trials sponsored, "EMD Serono Research & Development Institute, Inc." with 1 trials sponsored and "Helsinn Healthcare SA" with 1 trials sponsored. Other sponsors include 0 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Olsztyński Ośrodek Onkologiczny Kopernik sp. z o.o." #1 collaborator was "Hoffmann-La Roche" with 2 trials as a collaborator, "Cancer International Research Group (CIRG)" with 1 trials as a collaborator, "Eisai Europe Ltd. (United Kingdom)" with 1 trials as a collaborator, "Genentech, Inc." with 1 trials as a collaborator and "Merck KGaA, Darmstadt, Germany" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Olsztyński Ośrodek Onkologiczny Kopernik sp. z o.o." are "Breast Cancer" (4 trials), "Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification" (1 trials), "Chemotherapy-Induced Nausea and Vomiting" (1 trials), "Early Breast Cancer" (1 trials) and "Metastatic Urothelial Carcinoma" (1 trials). Many other conditions were trialed in "Olsztyński Ośrodek Onkologiczny Kopernik sp. z o.o." in a lesser frequency.

Most popular intervention types in "Olsztyński Ośrodek Onkologiczny Kopernik sp. z o.o." are "Drug" (11 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Docetaxel" (4 trials), "Carboplatin" (3 trials), "5-Fluorouracil" (2 trials), "Cyclophosphamide" (2 trials) and "Epirubicin" (2 trials). Other intervention names were less common.

The vast majority of trials in "Olsztyński Ośrodek Onkologiczny Kopernik sp. z o.o." are 5 trials for "All" genders, 5 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Olsztyński Ośrodek Onkologiczny Kopernik sp. z o.o.". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in Olsztyński Ośrodek Onkologiczny Kopernik sp. z o.o., undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Olsztyński Ośrodek Onkologiczny Kopernik sp. z o.o., 0 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".